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Abstract
One serious side effect of statin drugs is skeletal muscle myopathy. Although the mecha-
nism(s) responsible for statin myopathy remains to be fully determined, an increase in mus-
cle atrophy gene expression and changes in mitochondrial content and/or function have
been proposed to play a role. In this study, we examined the relationship between statin-in-
duced expression of muscle atrophy genes, regulators of mitochondrial biogenesis, and
markers of mitochondrial content in slow- (ST) and fast-twitch (FT) rat skeletal muscles.
Male Sprague Dawley rats were treated with simvastatin (60 or 80 mgkg-1day-1) or vehicle
control via oral gavage for 14 days. In the absence of overt muscle damage, simvastatin
treatment induced an increase in atrogin-1, MuRF1 and myostatin mRNA expression; how-
ever, these were not associated with changes in peroxisome proliferator gamma co-activa-
tor 1 alpha (PGC-1α) protein or markers of mitochondrial content. Simvastatin did, however,
increase neuronal nitric oxide synthase (nNOS), endothelial NOS (eNOS) and AMPK α-
subunit protein expression, and tended to increase total NOS activity, in FT but not ST mus-
cles. Furthermore, simvastatin induced a decrease in β-hydroxyacyl CoA dehydrogenase
(β-HAD) activity only in FT muscles. These findings suggest that the statin-induced activa-
tion of muscle atrophy genes occurs independent of changes in PGC-1α protein and mito-
chondrial content. Moreover, muscle-specific increases in NOS expression and possibly
NO production, and decreases in fatty acid oxidation, could contribute to the previously re-
ported development of overt statin-induced muscle damage in FT muscles.
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Introduction
Statin drugs lower blood cholesterol, and thus reduce the risk of coronary heart disease and
stroke, by inhibiting the rate limiting enzyme of the mevalonate pathway, 3-hydroxy-3-methyl-
glutaryl coenzyme A (HMG-CoA) reductase (for review see [1]). With reductions in low-
density lipoprotein (LDL) cholesterol of up to 55%, statins have become the most commonly
prescribed drug in the world today, with more and more populations being indicated for their
use [2,3]. Although generally well tolerated, one of the main side effects of statin medications is
skeletal muscle myopathy, with clinical symptoms that include muscle pain (myalgia), inflam-
mation (myositis), weakness, fatigue and cramping [4,5]. With an incidence of>10% of statin
users in the general population [6,7], hundreds of thousands of people worldwide are likely to
experience some form of statin-induced myopathy. Statin related muscle symptoms also ap-
pear to be exacerbated by exercise [8]. Thus, statin-induced myopathy has the potential to
markedly affect levels of physical activity and quality of life [9], and could prompt the discon-
tinuation of the statin therapy altogether. Therefore, a thorough understanding of the molecu-
lar mechanism(s) underlying statin myopathy is essential for the future identification of
specific biomarkers to detect adverse statin-induced events prior to the potential onset of
debilitating clinical symptoms and/or for the development of safer alternative cholesterol
lowering agents.
Although the exact mechanism(s) responsible for statin-induced myopathy remains to be
definitively determined, recent studies have suggested that mitochondria and/or the activation
of muscle atrophy-related genes may play a role (for reviews see [10–12]). For example, statins
have been shown to up regulate the expression of the muscle-specific ubiquitin proteasome sys-
tem (UPS) E3-ligases, atrogin-1 and MuRF1, in a range of model systems including statin-my-
opathy patients [13–18]. Importantly, statin-induced muscle atrophy/damage was markedly
reduced in myotubes from atrogin-1 knockout mice and in Zebra fish transfected with atrogin-
1 siRNA [14]. Together, these findings suggest that an increase in the expression of muscle spe-
cific E3-ligases (i.e. atrogin-1 and MuRF1) play a crucial role in statin-induced muscle fiber at-
rophy/damage and may help to explain muscle pain and weakness associated with statin-
myopathy.
Numerous clinical, animal and cell culture studies have provided evidence that statin-myop-
athy is also associated with impaired mitochondrial function and morphology (e.g. [17–29]).
In addition, recent studies also suggest that statins induce a reduction in mitochondrial con-
tent/volume [14,23,30–32]; an effect that could, in part, be due to reduced mitochondrial bio-
genesis. Mitochondrial biogenesis is positively regulated by a variety of signaling molecules and
transcriptional co-activators, including the peroxisome proliferator gamma co-activator 1
alpha (PGC1α) [33]. For example, PGC1α binds to and co-activates nuclear respiratory factor
1 (NRF1) which, in turn, regulates the transcription of mitochondrial transcription Factor A
(Tfam) [33]. Recent studies have reported a statin-induced reduction in PGC1αmRNA expres-
sion in humans, rodents and cultured cells [23,32]. Therefore, statins could down regulate mi-
tochondrial biogenesis via a reduction in PGC1α expression. Importantly, PGC1α has also
been proposed to play an inhibitory role against the activation of atrophy gene expression and
muscle atrophy [14,34,35]. Thus, a statin-induced decrease in PGC1α protein and/or co-tran-
scriptional activity could reduce mitochondrial biogenesis and also play a role in the induction
of atrophy gene expression. To date, however, no studies have examined the relationship, if
any, between changes in PGC1α protein, markers of mitochondrial content and the expression
of atrophy genes in skeletal muscle with in vivo statin treatment.
In contrast to their effect on PGC1α expression, non-muscle studies have shown that
statins also positively regulate two other important activators of mitochondrial biogenesis
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i.e. AMP-activated protein kinase (AMPK) [e.g. [36–39]], and nitric oxide (NO) via increases
in endothelial (eNOS) and neuronal (nNOS) nitric oxide synthase isoform expression and ac-
tivity [e.g.[40–43]]. Thus, statins may paradoxically also exert a stimulatory effect on mito-
chondrial biogenesis via an increase in AMPK and NOS activity. Interestingly, an increase in
skeletal muscle AMPK activity can also activate the expression of atrogin-1 and MuRF1, and
induce muscle fiber atrophy [for review see [44]], while nNOS has been implicated in the in-
duction of atrogin-1 and MuRF1 gene in various muscle atrophy models [45,46]. To date, how-
ever, no studies have examined the effect of statins on AMPK or NOS expression in skeletal
muscle in vivo.
Therefore, to gain a more complete understanding of the early molecular events associated
with statin-induced myopathy, the purpose of this study was to determine whether statin-in-
duced increases in muscle atrophy gene expression are associated with changes in: 1) PGC1α
protein expression; 2) mitochondrial enzyme activity and mitochondrial protein expression; 3)
AMPK protein expression and activation (phosphorylation); and 4) eNOS and nNOS protein
expression and total NOS activity.
Materials and Methods
Animals
Male Sprague Dawley rats (6–7 wk; 214.8 ± 11.1g, mean ± SEM) were obtained from the Bio-
logical Research Facility, The University of Melbourne, Victoria, Australia and kept at 22 ± 2°C
with ad libitum access to standard chow and water. All procedures used in this study were ap-
proved by The University of Melbourne Animals Experimentation Ethics Committee (Permit
#- 0704504.5).
Statin Dosage and Tissue Collection
In order to examine the early effect of statins on the induction of atrophy genes and signaling
molecules involved in mitochondrial biogenesis, independent of overt muscle damage and re-
generation, we employed doses of statin (simvastatin) that Mallinson et al. (2009) have previ-
ously shown to not induce overt damage and regeneration in rat skeletal muscle over a ~2 week
period. Therefore, rats were divided into three groups of 8 and treated for 14 days with vehicle
control or either 60 mgkg-1day-1 (Sim 60) or 80 mgkg-1day-1 (Sim 80) of simvastatin. (For a
detailed rationale for this dosing range, see the Discussion section of Mallinson et al, 2009).
Simvastatin (a gift from Pfizer Inc., Kent, UK) was suspended in 0.5% methyl cellulose and ad-
ministered via oral gavage at a dose of 5.0 ml.kg-1. Simvastatin has a half-life of ~ 2 hr in vivo
[47]. Vehicle control animals received 0.5% methyl cellulose vehicle by oral gavage at the same
relative volume for 14 days. Food consumption was monitored daily and rat body mass was
measured every morning prior to gavaging. On day 15, 24 hr following the last simvastatin or
vehicle treatment, rats were killed by intraperitoneal injection of pentobarbital sodium (325mg.
ml-1, Virbac, Australia) followed by cervical dislocation. Blood samples were immediately col-
lected via cardiac puncture. Based on previous studies that have shown a greater susceptibility
of fast-twitch muscles to statin-induced muscle damage/necrosis compared with slow-twitch
muscles in rodents [25,48–50], we compared the effect of statin treatment between the fast-
twitch extensor digitorum longus (EDL) and plantaris (PLT) muscles, and the slow-twitch sole-
us (SOL) muscle. As such, EDL, PLT and SOL muscles were rapidly collected and subjected to
the various measurements described below.
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Blood Cholesterol and Creatine Kinase Analysis
Plasma [CK] and [total cholesterol] were measured by Melbourne Health Pathology Service
(Royal Melbourne Hospital, Parkville, Victoria) using an Olympus 2700 Autoanalyser (Olym-
pus Diagnostics, Clare, USA).
Muscle Sample Preparation and Immunoblotting
For Western blot analysis, EDL, PLT and SOL muscles were crushed under liquid nitrogen and
aliquots homogenized using a Polytron PT-MR 1200 (Luzernerstrasse, Switzerland) in 10 vol-
umes of extraction buffer containing 50 mM Tris, 1 mM EDTA, 10% vol/vol glycerol, 1% vol/
vol Triton X-100, 50 mMNaF, 5 mMNa4P2O7, 1 mM DTT, 1 mM PMSF, 10g/ml of Trypsin
inhibitor (Sigma, St. Louis, MO, USA) and 5l/ml Protease Inhibitor Cocktail (P8340, Sigma,
St. Louis, MO) (pH 7.5). The resulting lysates were left on ice for 20 min and then spun at
10,000 g for 20 min at 4°C. Protein concentration was determined using a bicinchoninic acid
(BCA) protein assay (Pierce, Rockford, IL). Samples were then dissolved in Laemmli buffer
and subjected to electrophoretic separation by SDS-PAGE. Following electrophoretic separa-
tion, proteins were transferred to a PVDF membrane, blocked with 5% powdered milk in
PBST (Phosphate-buffered saline, 1% Tween 20) for 1 h followed by an overnight incubation at
4°C with primary antibody. Primary antibodies used were: rabbit anti-AMPK α-pan (1:1000,
Cell Signaling), rabbit anti-Thr172 phospho-AMPK (1:1000, Cell Signaling), rabbit anti-COX4
(1:1000, Cell Signaling), mouse anti-CytC (1:1000, Cell Signaling), mouse anti-eNOS (1:1000,
BD Bio Science), mouse anti-nNOS (1:1000, BD Bio Science), mouse anti-NRF-1 (1:1000,
Rockland), mouse anti-PGC-1α (1:1000, Chemicon), and mouse anti-Tfam (1:1000, GenWay).
The primary antibody was detected with IRDyeTM 800-conjugated anti-rabbit IgG (1:5000;
Rockland, Gilbertsville, PA) or IRDyeTM 680-conjugated anti-mouse IgG (1:5000; Molecular
Probes, Invitrogen) secondary antibodies and protein bands analyzed by infrared detection
(Odyssey Imaging system, LI-COR Biosciences, Lincoln, NE). Membranes were reprobed with
rabbit anti-GAPDH antibody (1:10000, Cell Signaling). To control for any differences in pro-
tein loading, the intensity of the protein band of interest was expressed relative to glyceralde-
hyde 3-phosphate dehydrogenase (GAPDH) band intensity from the same sample. Simvastatin
had no effect on GAPDH protein abundance in any of the three muscles examined in this
study (S1 Fig).
RNA extraction, Reverse Transcription and qPCR
Approximately 8–12 mg of crushed muscle was homogenised using a FastPrep1 instrument
(Qbiogene, Seven Hills, NSW) followed by RNA extraction using TRIzol1 reagent (Invitrogen,
Mulgrave, VIC) [51] combined with the PureLinkTM RNAMini Kit (Invitrogen, Mulgrave,
VIC), including DNase treatment, as per the manufacturers instruction. RNA concentration
and purity was determined using the NanoDrop 2000 spectrophotometer (NanoDrop prod-
ucts, Wilmington, DE). Samples were stored at -80°C until further use.
RNA was reverse transcribed to cDNA using Oligo-dT primers and the High Capacity
RNA-to-cDNA kit (Invitrogen, Mulgrave, VIC). Following reverse transcription, the samples
were treated with Ribonuclease H (RNase H) (Invitrogen, Mulgrave, VIC) at 37°C for 30 min-
utes to degrade any remaining RNA. Real-time polymerase chain reaction (RT-PCR) was per-
formed using a Stratagene Mx3000 thermocycler and a Brilliant1Multiplex QPCR master mix
(Integrated Sciences, Chatswood, NSW) as published previously [52]. The primer and probe
sets for atrogin-1, MuRF-1 and myostatin are provided in Table 1. mRNA expression was mea-
sured in triplicate and normalised to total cDNA as determined using the Quant-it OliGreen
ssDNA Assay Kit (Invitrogen, Mulgrave, VIC) [51].
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Mitochondrial Enzyme Activity
Citrate synthase (CS) and β-Hydroxyacyl CoA dehydrogenase (β-HAD) activities in an aliquot
of crushed muscle were measured spectrophotometrically as previously described [53]. Enzyme
activities were measured using a Multiskan EX photometric microplate absorbance reader and
Ascent software (Thermo Electron Corporation, Vantaa, Finland), and expressed per g of mus-
cle (μmol.min-1.g-1).
Nitric Oxide Synthase Activity
Total NOS activity was measured using 40–70 μg of protein as previously described [54]. NOS
activity was measured in whole cell lysates as the difference in activity between samples incu-
bated with or without Nω-nitro-L-arginine methyl ester (L-NAME). NOS activity was calculat-
ed as the amount of L-[




Relative body mass changes over the 14 day statin supplementation period was analyzed using
a two-way repeated measures ANOVA, and when a significant interaction was observed, with
Bonferoni post-hoc test. Three group comparisons between control and the two statin groups
were analyzed using a one-way ANOVA with Newman-Keul’s post-hoc test. Statistical signifi-
cance was set at p< 0.05. All data are presented as mean ± SEM. The statistical software pack-
age GraphPad Prism 5.00 was utilized for all statistical analysis.
Results
Plasma Creatine Kinase and Total Cholesterol
Previous studies have shown that simvastatin at 88 mgkg-1day-1, but not at 80 mgkg-1day-1,
induces significant damage in rat skeletal muscle that is accompanied by very large increases in
plasma CK activity (over 300-fold increase), an indirect marker of muscle damage [16]. There-
fore, in order to examine the effect of simvastatin, independent of overt muscle damage and re-
generation, we chose simvastatin doses [60 mg.kg-1day-1 (Sim 60) and 80 mgkg-1day-1 (Sim
80). Our results confirm that 14 d of simvastatin treatment induced only very minor increases
in plasma CK activity (1.34- and 1.18-fold for the Sim 60 and Sim 80 groups, respectively;
Table 1. Primers and probes used in RT-PCR.
Target Primer and probe sequence Primer Concentration (nM)
Atrogin-1 F 5’ ATG CCG TTC CTT GGT CAG 3’ 150
R 5’ ACT GCT GAG GTC GCT CAC 3’ 150
P 5’ TGC CGC TTT TCT CAT CCA 3’ 100
MuRF-1 F 5’ AGG ACT GAA TTT GTG TTA TAT GTT G 3’ 150
R 5’ TAG CCT CGA ACT CAT AGA GAT C 3’ 150
P 5’ AAC TGC CTC TGC CTC CA 3’ 100
Myostatin F 5’ AGA CAA CTT CTG CCC AGA G 3’ 50
R 5’ TCC GTG GTA GCG TGA TAA TC 3’ 500
P 5’ CCG TCA CTG CTG TCA TCC 3’ 200
F, forward primer; R, reverse primer; P, probe
doi:10.1371/journal.pone.0128398.t001
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p = 0.054, main effect, Fig 1A) compared to Control animals. Furthermore, plasma [total cho-
lesterol] was only reduced in the Sim 80 group compared to the Control (Fig 1B). These data
show that, although simvastatin (80 mg.kg-1.day-1) significantly decreased plasma cholesterol,
in agreement with the study of Mallinson et al. (2009), this dose induced only very minor in-
creases in plasma CK activity. Moreover, these results suggest that our simvastatin treatments
did not elicit overt skeletal muscle damage and regeneration.
Body Mass
Throughout the 2 wk treatment period, rats administered simvastatin exhibited no visible signs
of lethargy, altered gait or ruffled fur that would indicate marked statin toxicity or reduced mo-
bility. Furthermore, there were no significant differences in food consumption between the
groups (S2 Fig). There were, however, significant main effects for the relative increase in body
mass for simvastatin treatment and time, coupled with a significant interaction effect (Fig 2).
As such, by the end of treatment, the increase in body mass of the Sim 60 and Sim 80 groups
was 10% and 20% lower than the controls, respectively, with the increase in Sim 80 being lower
than Sim 60 over the last 6 days of treatment.
Fig 1. The simvastatin on plasma creatine kinase (CK) activity and total cholesterol. Rats were treated
with vehicle (Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. (A) Plasma CK
activity. (B) Plasma [total cholesterol]. *—significantly different from Control and Sim 60 groups.
Mean ± SEM. n = 8/group. One way ANOVA with Newman-Keul’s post-hoc test. P < 0.05.
doi:10.1371/journal.pone.0128398.g001
Simvastatin, Atrophy Genes and Mitochondrial Biogenesis
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Muscle Atrophy-Related Gene Expression
As shown in Fig 3, there was a significant increase in the expression of atrogin-1 and MuRF1
mRNA in the Sim 80 groups of all three muscles (Fig 3A–3F). Furthermore, there were signifi-
cant increases in atrogin-1 mRNA in the PLT and EDL Sim 60 groups (Fig 3B and 3C) and in
MuRF1 mRNA in the EDL Sim 60 group (Fig 3F).
A potential upstream regulator of atrogin-1 and MuRF1 expression is the TGF super family
member, myostatin [55,56]. Previous studies have shown that statins can increase the expres-
sion of another TGF super family member, TGF-β, and increase TGF-β signaling, in bone and
smooth muscle cells [57,58]. Thus, we sought to determine whether simvastatin would also in-
duce an increase in the expression of myostatin in skeletal muscle. Indeed, myostatin mRNA
was increased in the Sim 80 groups of all three muscles and also in the PLT Sim 60 group
(Fig 3G–3I).
PGC-1α, NRF-1 and Tfam Protein Expression
Simvastatin had no effect on PGC1α protein in any of the muscle types (Fig 4A–4C). This is
further supported by the finding that there was no change in the protein expression of two
downstream PGC1α targets, NRF-1 (Fig 4D–4F) and Tfam (Fig 4G–4I).
Markers of Mitochondrial Volume
The activity of citrate synthase (CS), a mitochondrial matrix enzyme from the Kreb’s Cycle, is
a commonly used marker of oxidative capacity/mitochondrial number [e.g. [59]]. Therefore,
we examined the effect of simvastatin treatment on CS activity and found no change in CS ac-
tivity in all three muscles (Fig 5A–5C). Furthermore, we found no changes in the expression of
electron transport chain proteins, cytochrome c oxidase subunit 4 (Cox4; Fig 5D–5F) and cyto-
chrome c (CytC; Fig 5H–5J).
Fig 2. The effect of simvastatin treatment on bodymass.Rats were treated with vehicle (Control) or
simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Body mass was normalized to each
rat’s initial starting mass (day 0). *—Sim 60 significantly different from Control. **—Sim 80 significantly
different from Sim 60. ***—Sim 80 significantly different from Control. Mean ± SEM. n = 8/group. Two way
ANOVA with repeated measures and Bonferonni’s post-hoc test. P < 0.05.
doi:10.1371/journal.pone.0128398.g002
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Beta-Hydroxyacyl-CoA-Dehydrogenase (-HAD) Activity
We next determined the effect of simvastatin on the activity of beta-hydroxyacyl-CoA-dehy-
drogenase (-HAD), an enzyme of the fatty acid -oxidation pathway. As shown in Fig 6, simva-
statin induced a significant decrease in -HAD activity in the EDL Sim 60 and Sim 80 groups
(Fig 6C), with a strong trend (p = 0.05, main effect) for a decrease in the PLT Sim 60 and Sim
80 groups (Fig 6B). There was no effect of simvastatin on -HAD activity in the SOL muscle.
AMPK
There was no difference in AMPKα Thr172 phosphorylation compared to Controls in all three
muscles (Fig 7A–7C). Simvastatin treatment did, however, induce an increase in total AMPKα
protein expression in the Sim 60 and Sim 80 groups of the EDL muscle (Fig 7F) but not in the
SOL or PLT muscles (Fig 7D and 7E).
Fig 3. The effect of simvastatin treatment on the expression of muscle atrophy-related genes, Atrogin-1, MuRF1 andMyostatin.Rats were treated
with vehicle (Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Muscle mRNA is extracted and analyzed as described in the
Methods. mRNA expression was normalised to total cDNA. *—significantly different from Control. Mean ± SEM. n = 6–8/group. One way ANOVA with
Newman-Keul’s post-hoc test. P < 0.05.
doi:10.1371/journal.pone.0128398.g003
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Nitric Oxide Synthase
Simvastatin induced an increase in eNOS protein expression in the EDL Sim 60 group (Fig 8C)
and increased nNOS protein expression in the EDL Sim 60 (Fig 8F) and PLT and EDL Sim 80
groups (Fig 8E and 8F). Given that simvastatin induced increases in eNOS and nNOS occurred
predominantly in the EDL muscle we next wanted to determine whether there would also be a
corresponding increase in total NOS activity in this muscle. Indeed, while not statistically sig-
nificant, total NOS activity in the EDL groups closely mirrored the changes in NOS protein ex-
pression (see S3 Fig).
Discussion
In this study, we sought to examine the relationship between the statin-induced increase in the
expression of the muscle atrophy-related genes, mitochondrial biogenesis-related signaling
molecules and markers of mitochondrial content. Our results show for the first time that
Fig 4. The effect of simvastatin treatment on the PGC1α, NRF-1 and Tfam protein expression. Rats were treated with vehicle (Control) or simvastatin at
60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Muscles were collected and subjected to Western blot analysis with the indicated antibodies as
described in the Methods. Values were normalised to GAPDH and expressed as arbitrary units (AU). Mean ± SEM. n = 8/group. One way ANOVA with
Newman-Keul’s post-hoc test.
doi:10.1371/journal.pone.0128398.g004
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Fig 5. The effect of simvastatin treatment on citrate synthase activity, and Cox4 and Cyt C protein expression.Rats were treated with vehicle
(Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Muscles were collected and subjected to enzyme activity analysis or
Western blot analysis with the indicated antibodies as described in the Methods. Protein expression values were normalised to GAPDH and expressed as
arbitrary units (AU). Mean ± SEM. n = 8/group. One way ANOVA with Newman-Keul’s post-hoc test.
doi:10.1371/journal.pone.0128398.g005
Fig 6. The effect of simvastatin treatment on β-HAD activity.Rats were treated with vehicle (Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1
(Sim 80) for 14 days. Muscles were collected and subjected to enzyme activity analysis as described in the Methods. *—significantly different from Control
(P < 0.05). #—strong trend for main effect (P = 0.05) compared to Control. Mean ± SEM. n = 8/group. One way ANOVA with Newman-Keul’s post-hoc test.
doi:10.1371/journal.pone.0128398.g006
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simvastatin increases the expression of UPS E3-ligase genes, atrogin-1 and MuRF1, not only in
predominantly fast-twitch/glycolytic muscles, but also in predominantly slow-twitch/oxidative
muscle. Furthermore, our results demonstrate that simvastatin also induces an increase in the
expression of TGF-β superfamily member, myostatin, in both fast- and slow-twitch muscles.
Importantly, we show that the expression of these atrophy-related genes was not associated
with changes in PGC1α protein, or with changes in markers of mitochondrial volume in either
muscle type. Finally, we show for the first time that simvastatin induced an increase in total
AMPK, eNOS and nNOS protein expression, and decreased the activity of fatty acid β-oxida-
tion enzyme, β-HAD in fast-twitch but not in slow-twitch muscle.
PGC1α is a major regulator of mitochondrial biogenesis and a recent study has reported
that patients with statin myopathy have reduced muscle PGC1αmRNA expression [23]. Fur-
thermore, 2 wk of statin treatment has been shown to reduce PGC1αmRNA expression in rat
skeletal muscle, while reductions in PGC1αmRNA and protein have been reported in cultured
cells [23,32]. A statin-induced decrease in PGC1α could help to explain reports that statin
myopathy is associated with a reduction in mitochondrial content [14,23,30–32,60] and an in-
crease in the activation of atrophy genes and muscle atrophy [14,34,35]. Our findings, however,
show that 2 wk of simvastatin treatment did not alter PGC1α protein expression (or the expres-
sion of downstream targets, NRF-1 and Tfam) or markers of mitochondrial content (e.g. Cox4
and Cyt C protein expression and CS activity), despite an increase in the expression of atrogin-
1, MuRF1 and myostatin. These findings show that the statin-induced increase in atrophy gene
expression occurs prior to any changes in PGC1α protein expression and mitochondrial con-
tent and suggest that other factors play a more important role in the initial statin-induced acti-
vation of atrophy genes.
Fig 7. The effect of simvastatin treatment on the AMPK Thr172 phosphorylation and total AMPK protein expression. Rats were treated with vehicle
(Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Muscles were collected and subjected to Western blot analysis with the
indicated antibodies as described in the Methods. Values for total AMPK were normalised to GAPDH. All values are expressed as arbitrary units (AU). *—
significantly different from Control. Mean ± SEM. n = 8/group. One way ANOVA with Newman-Keul’s post-hoc test. P < 0.05.
doi:10.1371/journal.pone.0128398.g007
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One factor such that could play a role in the activation of atrophy gene expression is statin-
induced mitochondrial dysfunction [17–29]. Indeed, Mallinson et al. recently reported that the
statin-induced increase in atrogin-1 mRNA was associated with an up regulation of the known
FoxO1 gene target pyruvate dehydrogenase kinase-4 (PDK4) expression, decreased pyruvate
dehydrogenase complex (PDC) activity and increased muscle glycogen content [16,18]. Impor-
tantly, pharmacological activation of the PDC by chronic dichloroacetate (DCA) treatment
was sufficient to blunt the up regulation of atrogin-1 mRNA [18]. Combined, these studies sug-
gest that statins may induce a decrease in glucose oxidation which could ultimately lead to glu-
cose intolerance, insulin resistance and the activation of FoxO target genes that include
atrophy-related genes [61–63]. An increase in muscle lipid content may also play a role in the
etiology of skeletal muscle insulin resistance [64]. As such, it is interest to note we show for the
first time that in vivo statin treatment reduced -HAD activity in fast-twitch muscle. Previous
studies have also reported that simvastatin increases LDL receptor content, LDL uptake, and li-
poprotein lipase (LPL) activity in skeletal muscle [65,66]. Thus, a statin-induced increase in
LDL uptake and LPL activity, combined with a statin-induced reduction in the capacity for
-oxidation of fatty acids, could also lead to a toxic lipid overload which may play a role in the
eventual development of insulin resistance and the activation of muscle atrophy genes, espe-
cially in fast-twitch muscle. Additional studies are therefore needed to further investigate the
molecular interaction between statins and mitochondrial fatty acid metabolism in vivo, and the
relationship with muscle atrophy gene expression.
AMPK is an important activator of mitochondrial biogenesis [67] and a potential activator
of myostatin, atrogin-1 and MuRF1 expression [44,68]. Numerous studies have shown that
Fig 8. The effect of simvastatin treatment on the nNOS and eNOS protein expression. Rats were treated with vehicle (Control) or simvastatin at 60 (Sim
60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days. Muscles were collected and subjected to Western blot analysis with the indicated antibodies as described in
the Methods. Values were normalised to GAPDH and expressed as arbitrary units (AU). *—significantly different from Control. Mean ± SEM. n = 6–8/group.
One way ANOVA with Newman-Keul’s post-hoc test. P < 0.05.
doi:10.1371/journal.pone.0128398.g008
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statins induce the activation of AMPK in vivo and in cultured cells (e.g. [36–39]), including in
L6 muscle cells [69]. In the present study, however, we found no evidence of sustained AMPK
activation 24 h after the last statin treatment, as indicated by the absence of an increase in
AMPK Thr172 phosphorylation. This result could mean that there was no statin-induced acti-
vation of AMPK or that any statin-induced activation of AMPK was transient and had re-
turned to baseline by 24 h. This later possibility is supported by the study of Sun et al. (2008)
that showed that the in vivo statin-induced increase in aortic and cardiac tissue AMPK activity
peak at ~4 h and had largely returned to baseline by 24 h. It remains unknown, however,
whether repeated transient activations of AMPK would be sufficient to induce skeletal muscle
atrophy gene expression in vivo. Clearly, if such activation did occur, it was not sufficient to
alter mitochondrial content. In this study, we also found that total AMPK protein was in-
creased by statin treatment in fast-twitch muscle. The implication of this finding is unclear but
it may suggest the potential for a greater AMPK signaling in response to a given stimulus. Fur-
ther research is therefore required to clarify the short and long term effects, if any, of statins on
skeletal muscle AMPK activity and muscle metabolism.
Studies in non-muscle cells have also established that statins promote an increase in eNOS
mRNA, protein content and activity, and NO production in endothelial tissue [70,71], in part,
via the inhibition of RhoA geranylgeranylation [for review see [72]]. This statin-induced inhi-
bition of RhoA geranylgeranylation leads to inhibition of RhoA membrane translocation and
activity, a decrease in Rho-associated kinase (ROCK) activity, and an increase in eNOS mRNA
stability that results in elevated levels of eNOS protein [40,73]. More recently, statins have also
been shown to increase nNOS mRNA and protein expression in non-skeletal muscle tissues/
cells, and this was also associated with reduced ROCK activity [42,43,74]. In the current study,
we demonstrate for the first time that statins can also induce increases in both eNOS and
nNOS protein in fast-twitch skeletal muscle. This result provides strong indirect evidence that
our simvastatin treatment induced an inhibition of RhoA/ROCK activity in fast-twitch muscle.
This finding is also consistent with a previous study that detected an early simvastatin-induced
inhibition of RhoA activity in rat fast-twitch muscle [16]. The reason for the lack of change in
eNOS/nNOS expression in the SOL muscle is, however, unclear. Perhaps, given that the basal
expression of nNOS (the major NOS isoform expressed in skeletal muscle cells) is very low in
slow-twitch muscles (see Fig 8D), other more dominant regulatory mechanisms may operate
in rat slow-twitch muscle to limit the up regulation of nNOS protein. Whatever the mecha-
nism, further research is warranted to explore the metabolic implications of the statin-induced
increase in NOS/NO in fast-twitch muscles.
Conclusion
In conclusion, our results show that in the absence of overt muscle damage, statin-induced in-
creases in muscle atrophy gene expression occurred independently of changes in the protein
expression of PGC1α, or with changes in markers of mitochondrial content. This study also
demonstrated for the first time that simvastatin treatment was sufficient to induce an increase
in AMPK, eNOS and nNOS protein expression, and to decrease the activity of fatty acid β-oxi-
dation enzyme, β-HAD, in fast- but not slow-twitch muscle. These fast-twitch muscle specific
changes may represent early events that could, in part, contribute to the previously reported
development of overt muscle damage in fast-twitch muscles/fibers.
Supporting Information
S1 Fig. Representative western blot images of GAPDH protein expression in Control and
Simvastatin treated muscles. Rats were treated with vehicle (C) or simvastatin at 60 (S60) and
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80 (S80) mg.kg-1.day-1 for 14 days. Muscles were collected and subjected Western blot analysis
as described in the Methods.
(TIF)
S2 Fig. Mean daily (S2 Fig 2A), and total (S2 Fig 2B), food consumption by Control and
Simvastatin treated rats. Rats were treated with vehicle (Control) or simvastatin at 60 (Sim
60) and 80 (Sim 80) mg.kg-1.day-1 for 14 days. Rats were housed in groups in 4 animals per
cage. Food was weighed prior to each daily dose of vehicle or simvastatin for 14 days.
Mean ± SEM. A. Two way ANOVA with Bonferoni’s post-hoc test (P> 0.05). B. One way
ANOVA with Newman-Keul’s post-hoc test (P> 0.05).
(TIF)
S3 Fig. The effect of simvastatin treatment on the EDL total NOS activity. Rats were treated
with vehicle (Control) or simvastatin at 60 (Sim 60) and 80 mg.kg-1.day-1 (Sim 80) for 14 days.
EDL muscles were collected and subjected to nitric oxide synthase (NOS) activity analysis as
described in the Methods. Mean ± SEM. n = 4–7/group. There was no significant differences
between any of the groups. One way ANOVA with Newman-Keul’s post-hoc test. P = 0.231.
(TIF)
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